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Background: Infarct-induced left ventricular (LV) remodeling is a deleterious consequence after acute myocardial
infarction (MI) which may further advance to congestive heart failure. Therefore, new therapeutic strategies to
attenuate the effects of LV remodeling are urgently needed. Salvianolic acid B (SalB) from Salviae mitiorrhizae,
which has been widely used in China for the treatment of cardiovascular diseases, is a potential candidate for
therapeutic intervention of LV remodeling targeting matrix metalloproteinase-9 (MMP-9).
Results: Molecular modeling and LIGPLOT analysis revealed in silico docking of SalB at the catalytic site of MMP-9.
Following this lead, we expressed truncated MMP-9 which contains only the catalytic domain, and used this active
protein for in-gel gelatin zymography, enzymatic analysis, and SalB binding by Biacore. Data generated from these
assays indicated that SalB functioned as a competitive inhibitor of MMP-9. In our rat model for cardiac remodeling,
western blot, echocardiography, hemodynamic measurement and histopathological detection were used to detect
the effects and mechanism of SalB on cardio-protection. Our results showed that in MI rat, SalB selectively inhibited
MMP-9 activities without affecting MMP-9 expression while no effect of SalB was seen on MMP-2. Moreover, SalB
treatment in MI rat could efficiently increase left ventricle wall thickness, improve heart contractility, and decrease
heart fibrosis.
Conclusions: As a competitive inhibitor of MMP-9, SalB presents significant effects on preventing LV structural
damage and preserving cardiac function. Further studies to develop SalB and its analogues for their potential for
cardioprotection in clinic are warranted.
Background
Due to therapeutic interventions that limit infarct size and
restore blood flow, short-term survival following a myocar-
dial infarction (MI) has greatly improved [1]. The conse-
quence of MI in patients is the left ventricular (LV)
remodeling which leads to congestive heart failure [2]. LV
remodeling accompanied with changes in heart wall struc-
ture, chamber geometry, and pump function is coordinated
through the synthesis and degradation of extracellular
matrix (ECM) [3]. ECM turnover is tightly regulated, parti-
c u l a r l yt h r o u g ht h em a t r i xm etalloproteinases (MMP), a
family of proteolytic enzymes [4]. Throughout the LV
remodeling process after MI, MMPs release from inflam-
matory and endogenous cells, degrade ECM, disengage
integrins, and stimulate reparative fibrosis [5]. Therefore,
developing specific MMP inhibitors is an important thera-
peutic strategy against post-MI remodeling. Earlier studies
have shown that MMP-9 is prominently over-expressed in
the early phase following MI which correlates with func-
tional deterioration of heart [6]. In addition, animals with
MMP-9 genetic deletion or deficiency have shown
improved preservation of cardiac function post-MI, sug-
gesting that MMP-9 is a potential target for cardiovascular
drug development [7-10].
Salviae Miltiorrhizae, one of the most important tradi-
tional herbal medicines, is widely used in clinic in
China, Japan, and other countries for the treatment of
* Correspondence: xshen@mail.shcnc.ac.cn; daguo@mail.shcnc.ac.cn
† Contributed equally
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
Shanghai 201203, China
Full list of author information is available at the end of the article
Jiang et al. BMC Pharmacology 2010, 10:10
http://www.biomedcentral.com/1471-2210/10/10
© 2010 Jiang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.coronary artery disease and other cardiovascular diseases
[11]. SalB, the most abundant and bioactive ingredient
of Salviae Miltiorrhizae, has raised a considerable inter-
est in recent years. It has been assigned as the marker
component of Salviae Miltiorrhizae in the Chinese
Pharmacopoeia. Our recent studies have shown that sal-
vianolic acids, which contains 65% of SalB, could signifi-
cantly inhibit MMP-9 but not MMP-2 activity at infarct
myocardium of rat with MI [12]. However, the molecu-
lar target of SalB has yet to be defined although multiple
pharmacological effects of SalB have reported.
In the current study, we demonstrated the direct bind-
ing of SalB to MMP-9 and association of the cardio-pro-
tection of SalB with its competitive inhibitory effect on
MMP-9 activity. These data will not only provide mole-
cular basis for SalB as MMP-9 inhibitor, but also sup-
port to further develop more selective MMP-9
inhibitors against cardiac remodeling.
Methods
Animal model
Wistar male rats (230-250 g) were purchased from
Shanghai Center of Experimental Animals, Chinese
Academy of Sciences. MI was introduced by ligating the
left anterior descending coronary artery near the main
pulmonary artery as described previously [12] Rats were
randomly assigned into four groups: sham operated rats
given saline (Sham, n = 30) or SalB (Sham-SalB, n =
20); MI rats given saline (MI, n = 20) or SalB (MI-SalB,
n = 20). After the surgery, saline or SalB (10 mg/kg)
was administered by daily intravenous injection for
2 weeks. Animals were euthanized at 8 weeks after
infarction. The hearts were harvest after arresting with a
cold hyperkalemic solution. The cardioprotective effects
of SalB were evaluated by echocardiography, hemody-
namic parameters, and histological stain. To detect the
protein expression level and activity of MMP-9 after MI,
MI rats (n = 10) were sacrificed at 24 h after MI.
“G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i m a l s ”
published by the US National Institutes of Health was
followed throughout the study.
Molecular Modeling
The three-dimensional structure of SalB was con-
structed using Corina online demonstration http://www.
molecular-networks.com/online_demos/corina_demo.
The model of MMP-9 protein with complete sequence
was retrieved from the Protein Data Bank (PDB) at the
Research Collaboratory for Structural Bioinformatics
http://www.RCSB.org. The PDB entry 2OVX was
selected for the three-dimensional structural model of
MMP-9, because it was an MMP-9/inhibitor complex
with the highest resolution among all available MMP-9
complex structures [13]. The docking of SalB to MMP-9
was calculated using version 3.0.5 of AutoDock.
Construction of catalytic domain of MMP-9
The full-length MMP-9 cDNA (MGC-12688) was pur-
chased from American Type Culture Collection. The
truncated catalytic domain of MMP-9 (MMP-9 CD)
comprising residues 107-216 and 391-444 was con-
structed and cloned into a pET-15b vector (Novagen),
resulting in expression plasmid pET15b-MMP-9 CD.
The recombinant protein MMP-9 CD was expressed in
E. coli. BL21 (DE3) strain using pET15b-MMP-9 CD.
The inclusion bodies were dissolved in 50 mM Tris-HCl
(pH 7.5), 10 mM CaCl2, 500 mM NaCl, 8 M urea, and
the protein was refolded by dialysis against urea free
buffer (50 mM Tris-HCl (pH 7.5), 10 mM CaCl2,
500 mM NaCl, 20 μMZ n C l 2, 10% glycerol) and finally
against the same buffer in which 20 μMZ n C l 2 and 10%
glycerol were omitted. MMP-9 CD was then purified to
homogeneity on zinc chelate chromatography column.
In-gel gelatin zymography
The enzymatic activities of MMP-9 CD or tissue sam-
ples were detected by in-gel gelatin zymography [12].
Tissue samples were detected at 24 h after infarction. In
brief, twenty μg protein from tissue or corresponding
amount of protein for MMP-9 CD was electrophoresed
in 10% SDS-PAGE under non-reducing conditions, con-
taining 1% gelatin as MMP substrate. After electrophor-
esis, the gel was rinsed in 1% Triton X-100 for 1 h,
washed in water, and incubated overnight in substrate
buffer containing 50 mM Tris-HCl, 5 mM CaCl2,a n d
150 mM NaCl (pH 7.5) at 37°C with gentle shaking.
Then, the gel was stained in 0.1% Coomassie Blue R-250
and destained using 10% methanol, 5% acetic acid solu-
tion. The protein species corresponding to MMP-9 were
quantified using a MiniBis system (DNR Bio-Imaging
Systems Ltd), and molecular weights were estimated
using Prestained SDS-PAGE standards (Hou-Bio Tech.
Ltd).
Real time binding measured by surface plasmon
resonance
The binding studies were performed using Biacore 3000
instrument (Biacore AB). All experiments were carried
out using HBS-EP (10 mM HEPES pH 7.4, 150 mM
N a C l ,3 . 4m ME D T Aa n d0 . 0 0 5 %s u r f a c t a n tP 2 0 )a s
running buffer with a constant flow rate of 30 μL/min
at 25°C. MMP-9 CD protein, 5.8 μMi n1 0m Ms o d i u m
acetate buffer (pH 3.73), was covalently immobilized
onto the CM5 sensor chip (BIAcore AB) using standard
primary amine coupling procedure. SalB was dissolved
in the running buffer with different concentrations
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BIAevaluation software, and the sensorgrams were pro-
cessed by automatic correction for nonspecific bulk
refractive index effects.
The mode of inhibition by SalB on MMP-9
The inhibitory effect of SalB on hydrolysis of thiopepto-
lide (Ac-Pro-Leu-Gly-S-Leu-Leu-Gly-OEt) by MMP-9
CD was determined as previously described with modifi-
cations [14]. Briefly, SalB at indicated concentrations
was incubated with MMP-9 CD (15 nM) in the reaction
mixtures containing 1 mM 5,5’-dithiobis-(2-nitrobenzoic
acid) at 4°C for 30 min. The reaction was then initiated
by adding thiopeptolide to the reaction mixture, and
monitored at 412 nm using Benchmark Plus™microplate
spectrophotometer (Bio-Rad) at room temperature.
Kinetic analysis of SalB against MMP-9 CD was calcu-
lated using double reciprocal plots of 1/V versus 1/[thio-
peptolide]. The slope of every double reciprocal plot is
the Km
app of enzyme at different SalB concentration.
Secondary plot was drawn through Km
app versus SalB
concentration. Km
app is apparent value of Km;K i is inhi-
bition constant; Ki was calculated using the equation
Ki=[Km][SalB]/(Km
app -Km).
Western blot for MMP-9
MMP-9 protein expression was detected at 24 h after
infarction. Total protein from the infarct area was
extracted and quantified. The aliquots of 20 μgp r o t e i n
were subjected to SDS-PAGE and the proteins were
transferred to nitrocellulose transfer membrane. The
membranes were then incubated with MMP-9 antibody
at a 1:1000 dilution. The bands of MMP-9 were visua-
lized by the chemiluminescence reagent and the density
of the band was quantified. To validate that same
amount of proteins were loaded on each lane; the mem-
brane was stained with amino black.
Functional assessment by echocardiography
Transthoracic echocardiography was performed using a
commercially available echocardiographic Vevo 770
high-resolution ultrasound scanner (VisualSonics Inc.,
Toronto, Ontario, Canada) equipped with an RMV716
linear-array transducer for rat. M-mode tracings were
used to measure LV wall thickness. Measurements were
averaged from ten different readings per rat.
Measurements of hemodynamic parameters
Eight weeks after surgery, the rats were anesthetized
with ketamine (100 mg/kg). A Mikro-tipped SPR-320
catheter (Millar Instruments Inc) was inserted through
the right carotid artery into left ventricle. Heart rate,
mean arterial pressure (MAP), left ventricular systolic
pressure (LVSP), end-diastolic pressure (EDP) of rats
from different treatment groups were recorded using
PowerLab 8/30 instrument (ADInstruments). Maximum
rate of pressure development (+dP/dtmax) and maximum
rate of relaxation (-dP/dtmin) were all derived or calcu-
lated from the continuously obtained pressure signal.
All the parameters were analyzed using Chart 5 Pro
software (ADInstruments).
Measurement of cardiac output
A TS420 flowmeter and a transonic perivascular MA2.5
PSL flow probe (Transonic Systems, NY, USA), suitable
for vessels of 0.7-1.2 mm OD, were used. The low-pass
filter was set at 160 Hz. Data was acquired using a
PowerLab recording unit at 1000 Hz. Briefly, rats were
anaesthetized with ketamine (100 mg/kg), placed on a
heating pad and ventilated. An upper two-thirds median
sternotomy was performed. The thymus lobes were
pulled apart to expose the aorta. The ascending aorta
was dissected and the probe was then positioned around
it. A micro-manipulator was used to carry the weight of
the probe. An appropriate amount of ultrasound trans-
mission gel was injected through the acoustic window of
the probe to fill the air space between the probe and the
aorta. Flow signals were found to be satisfactory
throughout the preparation.
Histopathological detection
The heart samples were fixed with 4% neutral-buffered
paraformaldehyde for 24 h, and the specimens were
paraffin-embedded, sliced at 5 μm, and stained with
haematoxylin and eosin. After staining, the sections
were rinsed with distilled water, dehydrated, and
mounted with Permount. Photomicrographs were
taken using an Olympus SZX7 Zoom stereo micro-
scope or BX51 microscope plus Olympus DP71 CCD
camera (Olympus Corporation). Software Image-
Pro Plus version 6.0 was used to detect the thickness
of LV.
Paraffin-embedded slices were also stained with 0.1%
picric sirius red (Sigma-Aldrich Inc, St Louis, USA) for
fibrillar collagen. Collagen volume fraction (CVF) was
expressed as a percentage of the total area of the field
occupied by collagen. Analysis of collagen type I and III
was performed using a polarized filter. Collagen type I is
characterized by a red/yellow and type III by green col-
lagen fibrils.
Data analysis
All quantitative values are given as mean ± S.E. Mean
values of data from different treatment groups were
compared using one-way ANOVA. After confirming
the equal variances, least-significant difference (LSD)
was used to compare the difference between groups.
P < 0.05 was considered to be statistically significant.
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SalB binds with MMP-9 according molecular docking and
LIGPLOT analysis
To elucidate the binding of SalB to MMP-9 protein,
docking studies were performed to gain insight into the
most probable binding conformation. The chemical
structure of SalB was shown in Fig. 1A. The 3D struc-
ture of SalB was constructed using Corina online
demonstration, and was shown in Fig. 1B. Structural
coordinate for MMP-9 protein (2OVX) was retrieved
from the Protein Data Bank, and AutoDock which can
predict the direct binding of proteins with small mole-
cule was adopted to verify the possible docking of SalB
to MMP-9. The data suggested that SalB almost occu-
pies the catalytic active sites of MMP-9 completely with
a dock score of -10.44 (Fig. 1C).
The LIGPLOT analyses were then introduced to help
to understand the in-depth interaction pattern between
SalB and the active site residues of MMP-9 protein.
Forty-four hydrophobic interaction atom pairs (between
carbon atoms of SalB and GLU111, HIS190, HIS401,
HIS405, HIS411, LEU187, LEU188, PHE110, VAL398)
have been identified using this method. In addition, 2
hydrogen bonds between SalB and MMP-9 protein were
detected (Fig. 1D). It is also noteworthy that the dis-
tance between SalB O6 (a carbonyl oxygen atom) and
zinc is 2.13 Å, suggesting the existence of a coordinated
bond between SalB and MMP-9. Because AutoDock
does not take coordinated bond formation into account,
the bonds between zinc and SalB might be under-
estimated.
SalB interacts with MMP-9 at catalytic domain
MMP-9 has several representative structural domains
(Fig. 2A). As described in detail in the method section,
we successfully constructed, expressed, and purified the
CAT domain that includes three FN(II) inserts (MMP-9
CD) for the binding and enzyme kinetic studies. The
sequence of the constructed peptide was shown in Fig.
2B. The recombinant MMP-9 CD displayed significant
collagenase activity using in-gel zymography assay, and
its’ activity on degradation of substrate was dose depen-
dent (Fig. 2C).
The bioreactive MMP-9 CD protein was then used to
verify the direct interaction between SalB and MMP-9,
employing plasmon resonance by BIAcore. Binding
kinetics of SalB and MMP-9 were found to be in a dose
dependent manner (Fig. 2D). The equilibrium dissocia-
tion constant (KD) for SalB was determined using steady
state affinity fit and calculated to be 39.5 μM. Taken
together, our data provided evidence for the direct bind-
ing of SalB to MMP-9.
SalB inhibits MMP-9 activity competitively
The double-reciprocal plots were obtained in the pre-
sence of various concentrations of thiopeptolide with or
without SalB. The mode of SalB inhibition was competi-
tive for MMP-9 CD (Fig. 3A), with the characteristics of
Figure 1 The molecular docking of SalB with MMP-9.( A)
Chemical structure of SalB. (B) 3D structure of SalB. (C) Docking
solution of SalB in the catalytic domain of MMP-9. Protein backbone
of MMP-9 (2OVX) is shown in cartoon model, and protein surface is
shown in transparency. Selected protein residues interacted with
SalB are shown in line model, SalB in stick model, and the yellow
dashed lines denote the hydrogen bonds between ligand and the
enzyme. (D) 2D representation of SalB and MMP-9 interaction was
analyzed using LIGPLOT. H-bond is represented as dashed line, and
spiked residue represents hydrophobic contacts.
Figure 2 Direct interaction between SalB and MMP-9 catalytic
domain.( A) Representative structural domains of MMP-9. (B) Amino
acid sequence of recombinant MMP-9 CD. (C) MMP-9 CD displayed
significant collagenase activity detected by zymography assay. (D)
Direct binding of SalB to MMP-9 by BIAcore analysis. The binding
affinity of SalB with MMP-9 CD was reflected by response unit (RU)
values. Immobilization of MMP-9 CD on the Biacore biosensor chip
resulted in a resonance signal of 8000 RUs. The kinetic
measurements were performed in triplicate using a set of serial
dilutions as shown.
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axis-intercepts and different slopes. The Ki value of SalB
on MMP-9 CD was calculated 79.2 μM (Fig. 3B).
To further confirm the inhibition of SalB on native
MMP-9, we performed In-gel zymography assay using
proteins isolated from MI rat heart because of the abun-
dance of MMP-9 and MMP-2 at 24 h. Briefly, the pro-
tein from infarct area was extracted, electrophoresed
and incubated in substrate buffer containing indicated
concentration of SalB at 37°C overnight. The activities
of MMP-9, MMP-2 decreased with the incubation of
SalB dose-dependently (Fig. 3C). The inhibition of SalB
on MMP-9 activity was 86.0 ± 1.5%, 87.3 ± 1.2% and
95.7 ± 1.2% at 25 μM, 50 μM and 100 μM. And the
inhibition of SalB on MMP-2 activity was 29.0 ± 4.9%,
68.0 ± 7.6% and 74.3 ± 7.2% at 25 μM, 50 μMa n d1 0 0
μM respectively (Fig. 3D), suggesting SalB is more speci-
fic on MMP-9 than on MMP-2.
SalB down-regulates MMP-9 activity instead of protein
expression at infarct area of MI rat hearts
It was reported that up-regulation of MMP-9 was found
during the first two weeks after myocardial infarction
[15]. To detect the inhibition of SalB on MMP-9 in vivo,
we evaluated the activity of MMP-9 in infarct heart of
rat after 24 h infarction using in-gel gelatin zymography
(Fig. 4A). MMP-9 activity was elevated in MI group
compared with Sham group (3.33 ± 0.10 fold; P < 0.05),
and this elevation was inhibited by SalB (Fig. 4B). No
significant regulation of SalB on MMP-2 activity was
found. To further clarify the regulation of SalB on
MMP-9 activity correlated with protein expression or
not, we performed Western blotting. Considerable
increase of MMP-9 protein was detected in MI group;
but treatment with SalB did not alter MMP-9 protein
expression (Fig. 4C; upside). Same amount of protein
loaded on each lane was verified by the stained mem-
brane using amino black (Fig. 4C; below). The quantifi-
cation data was shown in Fig. 4D, about 1.79 ± 0.27 fold
elevation for MMP-9 expression was found in MI group
compared with Sham group (P < 0.05).
SalB prevents the decrease of LV wall thickness
The effect of SalB treatment on LV remodeling was
investigated using echocardiography and histopathologi-
cal evaluation at 8 weeks after MI. The representative
echocardiography recordings (Fig. 5A), and histopatho-
logical structure (Fig. 5B) of whole heart, from four
group of animals are shown. In Sham and Sham-SalB
animals, concentric circle form of LV chamber and uni-
form wall thickness were quite evident (Fig.5B). How-
ever, significant dilatation of LV chamber was found in
MI group. Dilatation of asymmetric chamber in MI-SalB
g r o u pw a sr e d u c e dc o m p a r e dt h a tw i t hM Ia l o n e ,s u g -
gesting SalB may provide protective benefit against LV
remodeling. At a higher magnification, transmural myo-
cardial infarction and aneurysm were readily detected in
MI group at the position indicated by arrow, but were
absent in the other groups (Fig. 5C). Both LV anterior
Figure 3 SalB inhibits MMP-9 activity specifically and
competitively.( A) Kinetic analysis of SalB against MMP-9 CD
through double reciprocal plots of 1/V versus 1/[thiopeptolide]. (B)
Secondary plot of Km
app versus different SalB concentration. The Ki
of SalB against MMP-9 CD is calculated to be 79.2 μM. (C)
Representative zymography results for SalB inhibition on native
MMP-2, MMP-9 activity in vitro.( D) Quantitative data from Fig. 3C
for SalB inhibition on MMP-9, MMP-2 activity. (n = 3 independent
experiments).
Figure 4 Selective in vivo inhibition of SalB on MMP-9 activity
without down-regulating MMP-9 protein expression.( A) The
representative zymogram for in vivo MMP-9 and MMP-2 enzymatic
activities in each treatment group. (B) Quantification of data
presented in Fig.4B, expressed as fold increase versus Sham. (C)
Western blot analysis on MMP-9 expression in rats from each
treatment group (upper panel). Same amount of protein loaded on
each lane was verified by membrane stained with amino black
(lower panel). (D) Quantification of data presented in Fig. 4C.
Expression level of MMP-9 was expressed as fold increase versus
Sham. n = 10 for each group. All of the values are expressed as
mean ± S.E. *P < 0.05 versus Sham rats; #P < 0.05 versus MI rats.
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wall end-diastolic thickness (LVPWd) were decreased in
MI group compared with that of control when quanti-
fied using echocardiography (Fig. 5D and 5E) or histo-
p h a t h o l o g y( F i g .5 Fa n d5 G )m e a s u r e m e n t s .S u c h
decrease in wall thickness was alleviated considerably in
MI-SalB group.
SalB improves left ventricle contractility
The major haemodynamic parameters were measured to
evaluate the left ventricle contractility (Fig. 6). The left
ventricle dysfunction in the MI rats was confirmed with
a significant decrease of +dP/dtmax (4320.7 ± 198.9
mmHgS
-1 versus 11565.4 ± 942.3 mmHgS
-1, P <0 . 0 0 1 ) ,
-dP/dtmin (-3310.0 ± 288.6 mmHgS
-1 versus -11478.8 ±
819.5 mmHgS
-1, P < 0.001), MAP (96.1 ± 4.9 mmHg
versus 143.1 ± 5.6 mmHg, P < 0.001), LVSP (107.6 ±
5.0 mmHg versus 149.9 ± 5.4 mmHg, P < 0.001), and
increase of EDP (20.5 ± 4.4 mmHg versus 6.9 ± 1.7
mmHg, P < 0.05) compared to the Sham group. SalB
treatment partially reversed the impairment of left ven-
tricle function by improving values of measured para-
meters; +dP/dtmax (7151.1 ± 362.8 mmHgS
-1 versus
4320.7 ± 198.8 mmHgS
-1, P < 0.001), -dP/dtmin (-4634.2
± 357.0 mmHgS
-1 versus -3310.0 ± 288.6 mmHgS
-1, P <
0.05), MAP (124.8 ± 4.9 mmHg versus 96.1 ± 4.9
mmHg, P < 0.01), LVSP (134.4 ± 4.8 mmHg versus
107.6 ± 5.0 mmHg, P < 0.01) compared with MI group.
To further evaluate the cardiac function of rats in dif-
ferent groups, transonic flowmetery was used. Com-
pared with Sham group, MI rats had a decrease in value
of cardiac output from 52.7 ± 2.7 ml/min to 37.5 ±
1.6 ml/min (P < 0.001). In MI-SalB group, the cardiac
output reversed to 45.9 ± 1.9 ml/min (P < 0.01).
SalB prevents myocardiac fibrosis induced by MI
It is known that alteration of collagen deposition and
collagen type may contribute to congestive heart fail-
ure, likely involving MMPs. We investigated the effects
of SalB on myocardiac fibrosis to further our under-
standing of the mechanism of improved cardiac perfor-
mance by SalB treatment. Fig. 7A showed the
representative pictures of whole heart stained by Sirius
red. It was known that development of congestive
heart failure is associated with the increase in the ratio
of collagen type I/III. Fig. 7B showed the magnification
of Fig. 7A at the position indicated by arrows using a
polarized filter, through which the collagen I was
demonstrated as red/yellow and collagen III was
demonstrated as green. SalB markedly attenuated an
increase in collagen volume fraction in rats with MI,
and the quantitative data was shown in Fig. 7C (7.28 ±
0.39% versus 12.8 ± 2.21%; P < 0.001). Fig. 7D showed
that SalB not only reduced total fibrosis but also
decreased the ratio of collagen I/III in infarct area
(5.10 ± 0.86 versus 13.3 ± 3.8; P < 0.05).
Figure 5 SalB attenuates LV geometric changes induced by myocardial infarction.( A) Representative echocardiography recordings from
each treatment group. n = 20 for every group. (B) Representative histopathological patterns of whole heart from different treatment groups. n =
10 for every group. (C) Higher magnification (100X) of Fig. 5B for the area indicated by arrows. (D, E) Quantitative data of LVAWd (D) or LVPWd
(E) determined by echocardiography. (F, G) Quantitative data of LVAWd (F) or LVPWd (G) calculated using histopathology. *P < 0.05, ***P < 0.001
versus Sham rats; #P < 0.05, ###P < 0.001 versus MI rats.
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with MMP-9 CD
Our previous work showed that pyrocatechol and dan-
shensu were two main metabolites of SalB with oral
dosing in rat [16]. In this study, we examined the poten-
tial effect of these two SalB metabolites on MMP-9
activity using spectrophotometric enzyme and surface
plasmon resonance assays. No inhibition on MMP-9
activity was detected when pyrocatechol or sodium dan-
shensu at saturation concentration of 100 μM for each
compound was incubated with 50 nM of MMP-9 CD
(Fig. 8A). Similarly, no significant binding of pyrocate-
chol (Fig. 8B) or sodium danshensu (Fig. 8C) to MMP-9
C Dw a so b s e r v e d .O u rd a t as u g g e s t st h a ti ti su n l i k e l y
that the observed in vivo inhibitory effect of SalB on
MMP-9 comes from the two metabolites.
Discussion
MMPs, especially MMP-9, were considered to be one of
the major causes leading to extracellular matrix remo-
deling [17]. Thus, there is growing interest in MMP-9 as
a novel therapeutic target for the prevention of LV
remodeling. Here, we presented evidence demonstrating
for the first time that SalB bound to MMP-9 at the cata-
lytic domain, resulting in inhibition of MMP-9 activity
in vitro and in vivo. SalB did not exhibit significant
effect on MMP-2 activity and its inhibition on MMP-9
was unlikely derived from its main metabolites, pyroca-
techol and danshensu. Along with its regulation on
MMP-9 activity in vivo, SalB treatment also led to a less
impaired LV chamber geometry, attenuated myocardial
fibrosis, and thus improved heart performance of MI
rats.
Figure 6 Effects of SalB treatment on hemodynamic parameters. Maximum rate of pressure development (+dP/dtmax), maximum rate of
relaxation (-dP/dtmin), end-diastolic pressure (EDP), mean arterial pressure (MAP), Left ventricular systolic pressure (LVSP) and cardiac output were
demonstrated. All the values are expressed as mean ± S.E. *P < 0.05, ***P < 0.001 versus Sham rats; #P < 0.05, ##P < 0.01, ###P < 0.001 versus MI
rats. n = 20 for every group.
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Page 7 of 10Figure 7 SalB decreases fibrosis induced by MI.( A) Representative pictures of whole heart stained by Sirius red. The position of collagen
deposition was stained in red.(B) Higher magnification (100X) of areas in Fig. 7A indicated by arrows using a polarized filter. The collagen I was
demonstrated as red/yellow and collagen III was demonstrated as green. (C) Quantitative data of collagen volume fraction. (D) Quantitative data of
the ratio of collagen I/III in infarct area. **P < 0.01, ***P < 0.001 versus Sham rats; #P < 0.05, ###P < 0.001 versus MI rats. n = 10 for every group.
Figure 8 Main SalB metabolites do not bind MMP-9 CD nor inhibit its activity.( A) No inhibition was found for the two main metabolites
of SalB, pyrocatechol and sodium danshensu, on MMP-9 CD activity. (B, C) Biacore analysis for binding of compound with MMP-9. No
interaction was found for pyrocatechol (B) or sodium danshensu (C).
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nities for denatured fibrillar collagen, collagen type IV,
fibronection, laminin, elastin and proteoglycans [18].
The structures of MMP-2 and MMP-9 are highly simi-
lar; however, the three-dimensional structures of MMP-
2 or MMP-9 are unique among MMPs. The catalytic
domain of MMP-2 and MMP-9 carries an insert of
three fibronection type-II-like modules that mediates
interaction with the substrates [19]. The main differ-
ences between these two proteins are in the S1’ sub-
strate or selectivity pocket [20]. Kiyama et al. reported
that MMP-9 holds a pocket-like S1’ subsite with a floor-
board and MMP-2 has a channel-like S1’ subsite [21];
however, based on the results of docking analysis, the
different structure at S1’ subsite did not contribute to
the selectivity of SalB towards MMP-9 than MMP-2
because the binding sites of SalB on MMP-9 did not
locate at this domain. SalB showed a higher dock score
for MMP-9 than MMP-2, of -10.44 and -8.84 (data not
shown) respectively, suggesting that the higher Van der
Waals force between SalB and MMP-9 active sites con-
tributes to the selectivity.
Due to the prominent role of MMPs in physiological
and pathological processes, large endeavors were put to
develop pharmacological MMP inhibitors [22]. Several
MMP-9 inhibitors have been reported including AM-409
(phosphinic acid), RO-206-0222 (pyrimidine-2, 4, 6-
trione), An-1 and MJ-24 (carboxylat), and MS-560 (tri-
fluoromethyl hydroxamic acid inhibitor). Comparing with
these compounds, the docking sites of SalB on MMP-9
are very similar. Almost all of these compounds interact
with MMP-9 at the bulge-edge segment (Gly186, Leu188,
Ala189) and the S1’ wall (Leu418, Tyr420, Pro421, Tyr
423, Arg424). It is also a well known fact that most syn-
thetic MMP inhibitors contain a chelating group (hydroxa-
mic acid, carboxylate or thiol group) for zinc ligation and a
peptidic or peptidomimetic moiety that used the same
substrate binding sites [23]. Strikingly, SalB has a unique
structure compared to others listed above.
A growing body of literature supports a major role of
MMP inhibitor-PD166793 (C17H18BrNO4S) to counter
the maladaptive LV remodeling process in multiple ani-
mal models of congestive heart failure [24]. However,
major obstacles which prevent PD166793 and other
MMP inhibitors from further development are the ser-
ious side effects [25]. Salviae miltiorrhizae has been
used in China for many years to treat various diseases
including heart failure with little side effects [26]. As the
main component of Salviae miltiorrhizae,S a l Bi sc o n -
sidered to be a candidate as a single agent for clinic use.
Unlike PD166793 which has a broad spectrum of MMP
targets, we showed preliminary data suggesting that SalB
is probably a more selective towards MMP-9 compared
to other MMPs. Pharmacological effect of SalB was
demonstrated in MI rats in our study for improving
structure and function of impaired MI heart with no
obvious toxicity. It is quite hopeful that the unique
structure of SalB, and its relative selectivity towards
MMP-9, will enable us to explore the structure-activity
relationship to identify more specific and safer MMP-9
inhibitors for the treatment of cardiovascular disease.
Conclusions
Improvement of heart function after MI is directly asso-
ciated with inhibition of MMP-9 activity. In the current
work, we have provided in great detail of biochemical
analysis on SalB structure and its selective, competitive
inhibition on MMP-9 activity. We also examined poten-
tial downstream mechanism of SalB in regulating heart
geometry and function in MI rat model. The unique
structure of SalB and its specificity towards MMP-9 are
useful information for developing a new lead compound
of MMP-9 inhibitors to be test in clinic.
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